Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Long-Term Investments (2022 - 2024)

Historic Long-Term Investments for OptimizeRx (OPRX) over the last 3 years, with Q2 2024 value amounting to $434000.0.

  • OptimizeRx's Long-Term Investments changed N/A to $434000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $434000.0, marking a year-over-year change of. This contributed to the annual value of $568000.0 for FY2023, which is 9898.39% down from last year.
  • Latest data reveals that OptimizeRx reported Long-Term Investments of $434000.0 as of Q2 2024.
  • In the past 5 years, OptimizeRx's Long-Term Investments ranged from a high of $55.9 million in Q4 2022 and a low of $434000.0 during Q2 2024
  • In the last 3 years, OptimizeRx's Long-Term Investments had a median value of $568000.0 in 2023 and averaged $11.6 million.
  • Over the last 5 years, OptimizeRx's Long-Term Investments had its largest YoY gain of 9898.39% in 2023, and its largest YoY loss of 9898.39% in 2023.
  • Quarter analysis of 3 years shows OptimizeRx's Long-Term Investments stood at $55.9 million in 2022, then crashed by 98.98% to $568000.0 in 2023, then fell by 23.59% to $434000.0 in 2024.
  • Its Long-Term Investments was $434000.0 in Q2 2024, compared to $501000.0 in Q1 2024 and $568000.0 in Q4 2023.